Background: Interferon (IFN) beta is a safe and efficient drug for treating multiple sclerosis (MS). It is widely accepted that previously depressed patients may get worse when using IFN-beta. There are few reports on the association of IFN-beta and severe depression among patients without previous psychiatric history.
T wo types of recombinant human interferon (IFN) beta are in clinical use for treating multiple sclerosis (MS). The beneficial effect of IFN-beta in MS, as reviewed by Clerico et al, 1 probably results from different mechanisms of action, including a direct effect on plasma cells that modulate immunoglobulin G synthesis, an increase in interleukin (IL) 10 levels, inhibition of both IL-1A and tumor necrosis factor >, stimulation of IL-1 receptor antagonist production, and inhibition of proliferation of leukocytes. Additionally, these mechanisms also may include decreased antigen presentation in microglia, reduction of T-cell migration into the brain through inhibition of matrix metalloproteinases, and downregulation of adhesion molecules.
Interferon beta has been used worldwide to treat MS for nearly 20 years, and its efficacy and safety profile is well known. 2 Although some authors have not agreed that IFN-beta may induce depression, 3, 4 even the instructions leaflet accompanying the medication comes with warnings regarding depression as a possible side effect. The main concern regarding IFN-betaYinduced depression seems to lie among cases of patients with a previous history of depression. However, there are a few case reports of severe depression and suicidal ideation among patients with MS using IFN-beta, with no previous history of any psychiatric condition. In these cases, complete recovery was observed after the drug was withdrawn. 5Y7 Therefore, the issue cannot be ignored and poses an important issue regarding the follow-up of these patients.
The high prevalence of depression in MS 8 may mask some cases of IFN-betaYinduced depression. Strictly speaking, if depression were an adverse event relating to the use of IFN-beta, the right description of this condition would be that it was a Bsubstance-induced mood disorder,[ according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, criteria. 9 To date, few studies have concentrated on this subject, and no conclusions can be drawn.
The mechanism of action for an IFN-induced depressive reaction is debatable, and the majority of published studies have analyzed depression induced by IFN-alpha rather than IFNbeta. 10, 11 At least in relation to IFN-alpha administration, the resulting increased brain levels of L-kynurenine (and its metabolite, quinolinic acid) have been correlated with depressive symptoms. 12 To date, there have not been any investigations on the mechanism of action of IFN-beta in cases of depression.
The aim of the present paper was to report some cases of IFN-betaYinduced mood disorders that were characterized by severe depression with suicide ideation or even suicide attempts. The probability of a causal relationship between the depressive symptoms and IFN-beta was established using the Naranjo algorithm. 13, 14 
METHODS
The present study was approved by the ethics committees of all the institutions involved. It consists of a retrospective assessment of patients, who gave their full consent to these reports, provided that they were not identified in any way.
After a clinical discussion that took place on IFN-betaY induced depression in a patient with MS and no previous psychiatric symptoms, a call was made for neurologists in Brazil to send in any cases of possible IFN-betaYrelated severe depression and suicide ideation (or suicide attempts) that they had seen. The criteria for including the cases in the present report were as follows: diagnosis of relapsing-remitting MS (RRMS) according to the McDonald criteria, 15 patients who had not had any history of depression preceding the use of IFN-beta, severe depression with suicide ideation during the first year of IFN-beta treatment, complete remission of depression after IFN-beta withdrawal, assessment by a psychologist/psychiatrist at the initial consultation, assessment by a psychiatrist during the depressive phase, and at least 24 consecutive months of follow-up with the same neurologist. Other psychiatric symptoms present in the patients during the use of IFN-beta also were observed and reported. All formulations of IFN-beta were considered for this report: IFNbeta 1a 30 Hg intramuscularly (IM) per week (Avonex; Biogen Idec, Weston, Mass) or 22 or 44 Hg subcutaneously (SC) 3 times per week (Rebif; Merck Serono, Geneva, Switzerland), and IFNbeta 1b 250 Hg SC on alternate days (Betaferon or Betaseron; Bayer-Schering Pharma, Leverkusen, Germany). None of the patients had received corticosteroids immediately before the manifestation of psychiatric symptoms.
With the objective of characterizing severe depression in these patients, any cases without clear suicide ideation and/or attempts were not included in the present report. In accordance with the inclusion criteria established, none of the patients had any previous history of depression or other relevant psychiatric conditions. They had been adequately investigated by psychologists and/or psychiatrists during the standard initial routine assessment for MS patients in these specialized units. When the depressive symptoms with suicidal thoughts were identified by the neurologist in charge, the patients were fully assessed by a psychiatrist who recommended specific treatment for the psychiatric condition. In addition, all the patients were properly investigated at the time of depression, to rule out a demyelinating relapse with psychiatric manifestations in the early stages of the disease. 16, 17 The Naranjo algorithm was independently applied and analyzed by a blinded examiner. Only cases scoring 8 or more points in the algorithm were considered to be highly probable or definite drug-induced cases of severe depression.
RESULTS
A summary of all the cases is presented in Table 1 . Eleven cases of severe depression with suicide ideation and/or suicide attempts were retrospectively gathered from 6 MS units in Brazil. Nine of these cases completely fulfilled the inclusion criteria and are presented below (cases 1Y9). These patients presented psychiatric symptoms after using IFN-beta for an average period of 4 months. Two further cases of depression developing later than the first year of treatment are presented separately (cases 10 and 11).
The Naranjo algorithm for these cases is shown in Table 2 . All patients presented the value related to high probability of a drug-associated adverse event. Because of the severity of this psychiatric condition, none of the patients was restarted on IFN-beta after suspicion that this drug could be associated with suicide attempts or ideation. Therefore, the Naranjo question regarding reappearance of symptoms when the drug was restarted could not be answered for any of the cases.
Case Reports

Case 1
The subject is a female patient, 23 years old, diagnosed with RRMS in 2003. She started treatment with IFN-beta 1a 30 Hg IM per week. During the second month of treatment, she developed anhedonia and spent most of her time in her bedroom, reading about MS. After reading in an internet blog Web site that MS might be inherited by the child during the mother_s preg-nancy, she developed extreme anger against her mother and tried to kill her with a knife. Unable to do so, she slashed her own wrists. She was hospitalized, diagnosed with severe depression and psychotic thoughts, and received risperidone and sertraline. Interferon beta was withdrawn. For the subsequent 3 weeks, she showed great improvement in her psychological condition. She has now been followed up for 7 years without any relapse of depression. Over a 5-year period, she was treated with glatiramer acetate, but this drug was suspended 2 years ago because of disease progression.
Case 2
The subject is a female patient, 39 years old, diagnosed with RRMS in 2003. She started treatment with IFN-beta 44 Hg SC 3 times per week. After 6 unremarkable months, the patient developed severe depression with suicide ideation. The psychiatrist prescribed sertraline and recommended immediate withdrawal of IFN-beta. The patient showed gradual improvement over the subsequent 3 months and has been followed for 7 years without any relapse of the depressive symptoms. During this period, the patient has been receiving glatiramer acetate.
Case 3
The subject is a female patient, 29 years old, diagnosed with RRMS in 2004. She started treatment with IFN-beta 1a 30 Hg IM per week. During the second month of treatment, she gradually developed depression for a period of 2 weeks. She spent most of the time crying, and the family booked a new consultation at the MS unit. A physician close to the family prescribed haloperidol 1 mg/d while the patient awaited this new consultation. As soon as she received the haloperidol, she took 30 tablets at once. She was hospitalized and showed regrets that she had not tried to kill her 2-year-old daughter at the same time that she had attempted suicide, claiming that the world was a horrible place for a child. She was diagnosed with severe depression and psychotic thoughts and received olanzapine and fluoxetine. Interferon beta was withdrawn. For a 3-week period, she showed vast improvement in her psychological condition and could not understand why she had thought of killing herself or her daughter. She has now been followed for 7 years without any relapse of depression, undergoing treatment with glatiramer acetate.
Case 4
The subject is a male patient, 49 years old, diagnosed with RRMS in 2004. He started treatment with IFN-beta 1b, 250 Hg SC on alternate days. No remarkable findings were observed for the initial 9 months of treatment. After this period, the patient developed severe anhedonia, avoiding the presence of family and friends. He stopped working and spent many hours a day sitting on the sofa, missing meals, and not keeping up with personal hygiene to his usual standards. During a consultation with the psychiatrist at the MS unit, the patient admitted that he had considered suicide and mentioned many ways of doing so that he had thought of. He was diagnosed with severe depression and suicide ideation and received risperidone and sertraline. Interferon beta was withdrawn. For a 2-month period, he showed gradual improvement in his psychological condition, resuming his social life and habitual personal hygiene. He has now been followed for 6 years without any relapse of depression, undergoing treatment with glatiramer acetate.
Case 5
The subject is a female patient, 34 years old, diagnosed with RRMS in 2005. She started treatment with IFN-beta 1a 22 Hg SC 3 times per week but developed severe headache after every injection, and the medication was changed to IFN-beta 1a 30 Hg IM per week. During the first month of this treatment, the patient developed severe depression and suicide ideation, mentioning a strong desire for death. She became aggressive toward others and showed signs of auto-aggressive behavior. On a psychiatrist_s recommendation, IFN-beta was withdrawn, with immediate amelioration of symptoms. The patient refused further treatment and remained without immunomodulators for the following 3 years. After another demyelinating episode, the patient agreed to receive glatiramer acetate, and she has been undergoing this treatment for the last 2 years.
Case 6
The subject is a female patient, 35 years old, diagnosed with RRMS in 2005. She started treatment with IFN-beta 1a 44 Hg SC 3 times per week. After 6 unremarkable months, the patient developed a progressive state of anhedonia, losing interest in her usual activities and avoiding going out of the house. Considering this could be just a Bphase,[ she did not seek medical attention at that time. During the subsequent 2 months, the patient became anorexic, losing 15% of her body weight. She also developed severe depression with suicidal thoughts. The psychiatrist prescribed sertraline and amitriptyline and recommended immediate withdrawal of IFN-beta. For the next month, the patient showed gradual improvement of her psychological condition, and after 1 more month, she was asymptomatic. For the last 5 years, she has been undergoing treatment with glatiramer acetate.
Case 7
The subject is a female patient, 19 years old, diagnosed with RRMS in 2007. She started treatment with IFN-beta 1a 30 Hg IM per week, and after 3 months, she developed mood disturbances with hypersexuality and aggressive behavior. She was hospitalized in the fourth month of treatment and attempted suicide while in the hospital. The psychiatrist diagnosed severe depression and recommended immediate withdrawal of IFNbeta. During the subsequent 2 months, her behavior returned to normal. She remained without any medication for 2 years, and then, after another demyelinating episode, she was started on azathioprine. Because of her poor neurological response to this medication, she has now started treatment with glatiramer acetate. For the last 3 years, she has not shown any relapse of her depressive symptoms or behavioral abnormalities.
Case 8
The subject is a female patient, 40 years old, diagnosed with RRMS in 2004. She started treatment with IFN-beta 1a 44 Hg SC 3 times per week in 2005. One year later, she developed severe depression, suicide ideation, and recurrent panic attacks, requiring several hospitalizations at a psychiatric unit during the following 3 years. Because of a new severe demyelinating episode and new lesions at the magnetic resonance imaging, her medication was changed to glatiramer acetate. Her depressive symptoms disappeared and did not reappear during her 2-year follow-up period.
Case 9
The subject is a male patient, 32 years old, diagnosed with RRMS in 1998. He started treatment with IFN-beta 1b, 250 Hg SC on alternate days in 1999 and made very irregular use of this medication. Six years later, because of an increase in the relapse rate, the patient started using IFN-beta on a regular basis. He developed severe depression with suicide ideation within 2 months. He stopped all his professional activities and received several antidepressant drugs, all to no avail. After a period of 3 years, IFN-beta was withdrawn, and the patient showed immediate improvement in his depression, returning to work and resuming his social life. He has now been followed for 2 years without any relapse of depression. During the last 15 months, he has been undergoing treatment with glatiramer acetate, without psychiatric symptoms.
The following 2 cases had been undergoing treatment with IFN-beta for longer than 1 year when they presented severe depression. Although they did not fulfill the criterion of early development of depression, they were very typical and are presented below.
Case 10
The subject is a female patient, 33 years old, diagnosed with RRMS in 2006. She started treatment with IFN-beta 1a 44 Hg SC 3 times per week. After 2 unremarkable years, the patient presented acute and severe depression, attempting suicide through ingestion of large amounts of her father_s medications (biperiden hydrochloride, pramipexole, and clonazepam). She was hospitalized in an intensive care unit, presenting severe exogenous intoxication. Interferon-beta was immediately withdrawn, and the patient started treatment with risperidone and paroxetine. One week later, she was released from the hospital and could not understand why she had attempted suicide. She decided not to take any more immunomodulatory drugs, afraid that the depressive symptoms could reappear. She has been followed for 2 years, without any relapse of depression.
Case 11
The subject is a female patient, 26 years old, diagnosed with RRMS in 2002. She started treatment with IFN-beta 1a 44 Hg SC 3 times per week, and for 6 years, she remained on this treatment, presenting severe depression with suicide ideation throughout this period. Her antidepressant drugs were changed 6 times to no avail. She also developed menstrual disorders with no evident hormonal abnormalities. Interferon beta was withdrawn after 6 years, and she started treatment with glatiramer acetate. Her depressive symptoms disappeared. After 1 year of glatiramer acetate, she underwent autologous stem cell transplantation and has not used immunomodulatory drugs since then. She has been followed for 2 years without any relapse of depression.
DISCUSSION
Interferon beta is a safe and efficient treatment for MS. 18Y20 All formulations of this drug are used worldwide, and many patients benefit from this treatment. The aim of the present paper was not to cast a shadow on IFN-beta as a safe and efficient treatment for MS but to alert physicians to a potentially dangerous side effect that can occur in some patients.
Although it is generally accepted that IFN-beta should be avoided among MS patients with a history of depression, 21 little is known about cases of severe psychiatric disorders that can be induced by this drug. The literature on the subject is sparse, 5Y7 and physicians attending patients with MS and severe depression may consider the depressive syndrome to be associated with MS rather than being drug induced. In fact, it is very likely that depression in a patient with MS is not drug related at all, but the possibility that there may be such a relationship must be taken into consideration.
The neuropsychiatric adverse events of IFN-alpha are well established, as recently reviewed by Raison et al. 11 At least for IFN-alpha, severe depression that can be accompanied by manic and/or psychotic thoughts manifesting over the initial weeks or months of treatment are recognized to occur in 21% to 58% of patients. 11 This risk is higher for patients with a previous psychiatric history, but the vulnerability to developing depression during the use of IFN-alpha is so high that some studies even recommend concomitant use of antidepressants. 22, 23 Diseases requiring treatment with IFNs are usually associated with depression and fatigue, 24 and very high rates of depressive symptoms are identified when physicians think about this possibility. Raison et al 11 even mention that depression under these conditions is a matter of Bseek and you will find it.[ The present work attempted to avoid such bias by concentrating only on very severe cases of depression that were associated with suicide ideation and attempts. Assessing the role of drugs in suicide ideation and attempts is particularly difficult, 25 but reports such as this one may help to raise physicians_ awareness of this possibility.
The absence of depression during the use of glatiramer acetate by these patients goes beyond the scope of the present paper. Therefore, it will not be discussed here.
Finally, the cases reported here also show that severe depression associated with IFN-beta may present with significant psychotic or manic behavior. Once the patients stopped treatment with IFN-beta, they typically mentioned that they could not even understand what had happened to them. Indeed, the symptoms of these patients would be better described as a psychiatric syndrome that goes beyond pure depression. 26 This could help physicians to identify such cases, which are not at all typical of the usual depressive syndrome associated with MS.
